New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
GPR141 regulates breast cancer progression via oncogenic mediators and the p-mTOR/p53 axis: Study

GPR141 regulates breast cancer progression via oncogenic mediators and the p-mTOR/p53 axis: Study

by Impact Journals LLCSchematic demonstrating the role of GPR141 in mediating breast cancer development and progression. Credit: 2023 Parija et al.A new research paper was published inOncotarget
World medicine December 05,2023
GPR141 regulates breast cancer progression via oncogenic mediators and the p-mTOR/p53 axis: Study

GPR141 regulates breast cancer progression via oncogenic mediators and the p-mTOR/p53 axis: Study

by Impact Journals LLCSchematic demonstrating the role of GPR141 in mediating breast cancer development and progression. Credit: 2023 Parija et al.A new research paper was published inOncotarget
World medicine December 05,2023
FTD/TPI plus oxaliplatin well-tolerated but not broadly effective as treatment for esophageal cancer

FTD/TPI plus oxaliplatin well-tolerated but not broadly effective as treatment for esophageal cancer

by Roswell Park Comprehensive Cancer CenterCredit: Unsplash/CC0 Public DomainA recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive C
World medicine December 05,2023
FTD/TPI plus oxaliplatin well-tolerated but not broadly effective as treatment for esophageal cancer

FTD/TPI plus oxaliplatin well-tolerated but not broadly effective as treatment for esophageal cancer

by Roswell Park Comprehensive Cancer CenterCredit: Unsplash/CC0 Public DomainA recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive C
World medicine December 05,2023
Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

by Elana GotkineFor patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival, according to a st
World medicine December 05,2023
Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

by Elana GotkineFor patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival, according to a st
World medicine December 05,2023
FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

by Lori SolomonThe U.S. Food and Drug Administration approvedLynparza(olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterio
World medicine December 05,2023
FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

by Lori SolomonThe U.S. Food and Drug Administration approvedLynparza(olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterio
World medicine December 05,2023
FDA approves Akeega for BRCA-positive metastatic prostate cancer

FDA approves Akeega for BRCA-positive metastatic prostate cancer

by Lori SolomonThe U.S. Food & Drug Administration has approvedAkeega(niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate can
World medicine December 05,2023
FDA approves Akeega for BRCA-positive metastatic prostate cancer

FDA approves Akeega for BRCA-positive metastatic prostate cancer

by Lori SolomonThe U.S. Food & Drug Administration has approvedAkeega(niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate can
World medicine December 05,2023
FDA provides accelerated approval of Talvey for multiple myeloma

FDA provides accelerated approval of Talvey for multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approvedTalvey(talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.Theaccelerated approvalis fo
World medicine December 05,2023
FDA provides accelerated approval of Talvey for multiple myeloma

FDA provides accelerated approval of Talvey for multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approvedTalvey(talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.Theaccelerated approvalis fo
World medicine December 05,2023
Epkinly granted accelerated FDA approval for lymphoma treatment

Epkinly granted accelerated FDA approval for lymphoma treatment

by Lori SolomonThe U.S. Food and Drug Administration has granted accelerated approval for Genmab'sEpkinly (epcoritamab-bysp)for relapsed or refractory diffuse large B-cell lymphoma (DL
World medicine December 05,2023
Epkinly granted accelerated FDA approval for lymphoma treatment

Epkinly granted accelerated FDA approval for lymphoma treatment

by Lori SolomonThe U.S. Food and Drug Administration has granted accelerated approval for Genmab'sEpkinly (epcoritamab-bysp)for relapsed or refractory diffuse large B-cell lymphoma (DL
World medicine December 05,2023
DNA repair discoveries hold promise for new approaches to cancer treatment

DNA repair discoveries hold promise for new approaches to cancer treatment

byNYU Langone HealthA depiction of the double helical structure of DNA. Its four coding units (A, T, C, G) are color-coded in pink, orange, purple and yellow. Credit: NHGRIDNA can be damaged by
World medicine December 05,2023
DNA repair discoveries hold promise for new approaches to cancer treatment

DNA repair discoveries hold promise for new approaches to cancer treatment

byNYU Langone HealthA depiction of the double helical structure of DNA. Its four coding units (A, T, C, G) are color-coded in pink, orange, purple and yellow. Credit: NHGRIDNA can be damaged by
World medicine December 05,2023
DNA discovery may assist in fight against aggressive cancer

DNA discovery may assist in fight against aggressive cancer

byUniversity of OtagoGraphical abstract. Credit:iScience(2023). DOI: 10.1016/j.isci.2023.106986In a significant development in the fight against fatal cancers, University of Otago re
World medicine December 05,2023
DNA discovery may assist in fight against aggressive cancer

DNA discovery may assist in fight against aggressive cancer

byUniversity of OtagoGraphical abstract. Credit:iScience(2023). DOI: 10.1016/j.isci.2023.106986In a significant development in the fight against fatal cancers, University of Otago re
World medicine December 05,2023
DNA test could broaden access to cervical cancer screening

DNA test could broaden access to cervical cancer screening

by Jade Boyd,Rice UniversityA low-cost, point-of-care DNA test for HPV infections that was invented at Rice University delivers results in 45 minutes and requires just two pieces of equipment, a
World medicine December 05,2023
DNA test could broaden access to cervical cancer screening

DNA test could broaden access to cervical cancer screening

by Jade Boyd,Rice UniversityA low-cost, point-of-care DNA test for HPV infections that was invented at Rice University delivers results in 45 minutes and requires just two pieces of equipment, a
World medicine December 05,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com